Income Statement

v3.8.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Revenue:    
Grant and licensing revenue $ 1,519,943 $ 341,643
Operating expenses:    
Research and development 8,267,549 9,330,677
General and administrative 6,370,954 4,138,285
Change in fair value of contingent consideration 224,289
Total operating expenses 14,862,792 13,468,962
Loss from operations (13,342,849) (13,127,319)
Interest income 22,167 31,142
Other income, net 101,276 670,781
Interest expense (549,403)
Total non-operating income (expenses), net 123,443 152,520
Net loss before income tax benefit (13,219,406) (12,974,799)
Income tax benefit 809,540
Net loss (12,409,866) (12,974,799)
Net loss - non-controlling interest (568,195) (400,847)
Net loss attributable to Heat Biologics, Inc. $ (11,841,671) $ (12,573,952)
Net loss per share attributable to Heat Biologics, Inc.- basic and diluted $ (3.08) $ (7.15)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted 3,845,342 1,758,621
Other comprehensive loss:    
Net loss $ (12,409,866) $ (12,974,799)
Unrealized (loss) gain on foreign currency translation (93,794) 14,353
Total comprehensive loss (12,503,660) (12,960,446)
Comprehensive loss - non-controlling interest (568,195) (400,847)
Comprehensive loss attributable to Heat Biologics, Inc. $ (11,935,465) $ (12,559,599)

Source